Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025
Apyx Medical Corporation (NASDAQ:APYX), a manufacturer of advanced helium plasma and radiofrequency technology, will release its Q2 2025 financial results on August 7, 2025, after market close. The company will host a conference call at 4:30 PM ET the same day.
Apyx Medical specializes in the Renuvion® and AYON Body Contouring System™ for the cosmetic surgery market, and J-Plasma® for hospital surgical applications. Their technology's effectiveness is backed by over 90 clinical publications, demonstrating their strong presence in the advanced energy technology sector.
Apyx Medical Corporation (NASDAQ:APYX), produttrice di tecnologie avanzate a plasma di elio e radiofrequenza, pubblicherà i suoi risultati finanziari del secondo trimestre 2025 il 7 agosto 2025, dopo la chiusura dei mercati. La società terrà una conference call lo stesso giorno alle 16:30 ET.
Apyx Medical è specializzata nel sistema Renuvion® e AYON Body Contouring System™ per il mercato della chirurgia estetica, e in J-Plasma® per applicazioni chirurgiche ospedaliere. L’efficacia della loro tecnologia è supportata da oltre 90 pubblicazioni cliniche, a testimonianza della loro solida presenza nel settore delle tecnologie energetiche avanzate.
Apyx Medical Corporation (NASDAQ:APYX), fabricante de tecnología avanzada de plasma de helio y radiofrecuencia, publicará sus resultados financieros del segundo trimestre de 2025 el 7 de agosto de 2025, después del cierre del mercado. La compañía realizará una llamada conferencia el mismo día a las 4:30 PM ET.
Apyx Medical se especializa en el sistema Renuvion® y AYON Body Contouring System™ para el mercado de cirugía estética, y en J-Plasma® para aplicaciones quirúrgicas hospitalarias. La efectividad de su tecnología está respaldada por más de 90 publicaciones clínicas, demostrando su fuerte presencia en el sector de tecnología energética avanzada.
Apyx Medical Corporation (NASDAQ:APYX)는 첨단 헬륨 플라즈마 및 고주파 기술 제조업체로, 2025년 8월 7일 장 마감 후 2025년 2분기 재무 실적을 발표할 예정입니다. 회사는 같은 날 오후 4시 30분 ET에 컨퍼런스 콜을 진행합니다.
Apyx Medical은 미용 수술 시장을 위한 Renuvion® 및 AYON Body Contouring System™과 병원 수술용 J-Plasma®를 전문으로 합니다. 이들의 기술 효과는 90건 이상의 임상 논문으로 뒷받침되어 첨단 에너지 기술 분야에서 강력한 입지를 보여줍니다.
Apyx Medical Corporation (NASDAQ:APYX), fabricant de technologies avancées au plasma d’hélium et à radiofréquence, publiera ses résultats financiers du deuxième trimestre 2025 le 7 août 2025, après la clôture des marchés. La société tiendra une conférence téléphonique le même jour à 16h30 ET.
Apyx Medical est spécialisée dans le système Renuvion® et AYON Body Contouring System™ pour le marché de la chirurgie esthétique, ainsi que dans J-Plasma® pour les applications chirurgicales hospitalières. L’efficacité de leur technologie est soutenue par plus de 90 publications cliniques, démontrant leur forte présence dans le secteur des technologies énergétiques avancées.
Apyx Medical Corporation (NASDAQ:APYX), ein Hersteller von fortschrittlicher Heliumplasma- und Radiofrequenztechnologie, wird seine Finanzergebnisse für das zweite Quartal 2025 am 7. August 2025 nach Börsenschluss veröffentlichen. Das Unternehmen veranstaltet am selben Tag um 16:30 Uhr ET eine Telefonkonferenz.
Apyx Medical ist spezialisiert auf das Renuvion® und AYON Body Contouring System™ für den kosmetischen Chirurgiemarkt sowie J-Plasma® für chirurgische Anwendungen im Krankenhaus. Die Wirksamkeit ihrer Technologie wird durch über 90 klinische Veröffentlichungen belegt, was ihre starke Präsenz im Bereich der fortschrittlichen Energietechnologie unterstreicht.
- None.
- None.
CLEARWATER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the second quarter of fiscal year 2025 will be released after markets closes on Thursday, August 7th.
Management will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 7th, to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 35370. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will also be archived for future reference.
Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and now the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical publications. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com
FAQ
When will Apyx Medical (NASDAQ:APYX) release Q2 2025 earnings?
How can investors access Apyx Medical's Q2 2025 earnings call?
What are the main products of Apyx Medical Corporation?
How many clinical publications support Apyx Medical's technology?
